Log in

Fluidigm Stock Price, Forecast & Analysis (NASDAQ:FLDM)

$2.33
-0.18 (-7.17 %)
(As of 11/19/2019 05:39 AM ET)
Today's Range
$2.33
Now: $2.33
$2.50
50-Day Range
$2.33
MA: $4.10
$5.18
52-Week Range
$2.27
Now: $2.33
$14.90
Volume595,600 shs
Average Volume1.28 million shs
Market Capitalization$162.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$112.96 million
Book Value$1.46 per share

Profitability

Net Income$-59,010,000.00

Miscellaneous

Employees535
Market Cap$162.10 million
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.


Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) issued its earnings results on Tuesday, November, 5th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.01. The medical research company earned $26.50 million during the quarter, compared to analysts' expectations of $28.74 million. Fluidigm had a negative net margin of 57.10% and a negative return on equity of 25.11%. The firm's quarterly revenue was down 8.5% compared to the same quarter last year. During the same period last year, the company posted ($0.13) earnings per share. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Fluidigm.

What price target have analysts set for FLDM?

4 brokerages have issued 12-month target prices for Fluidigm's shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $12.67 in the next year. This suggests a possible upside of 443.6% from the stock's current price. View Analyst Price Targets for Fluidigm.

What is the consensus analysts' recommendation for Fluidigm?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

Media headlines about FLDM stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fluidigm earned a news sentiment score of -4.6 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Fluidigm.

Are investors shorting Fluidigm?

Fluidigm saw a drop in short interest in October. As of October 31st, there was short interest totalling 1,460,000 shares, a drop of 8.8% from the September 30th total of 1,600,000 shares. Based on an average trading volume of 914,300 shares, the short-interest ratio is presently 1.6 days. Approximately 2.1% of the company's stock are sold short. View Fluidigm's Current Options Chain.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (5.78%), Cadence Capital Management LLC (0.39%), Perkins Capital Management Inc. (0.33%), Assenagon Asset Management S.A. (0.30%), State of New Jersey Common Pension Fund D (0.30%) and California Public Employees Retirement System (0.18%). Company insiders that own Fluidigm stock include Levin Capital Strategies, LP, Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Institutional Ownership Trends for Fluidigm.

Which institutional investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., SG Americas Securities LLC, Perkins Capital Management Inc., Cerity Partners LLC and Nisa Investment Advisors LLC. Company insiders that have sold Fluidigm company stock in the last year include Levin Easterly Partners Llc and Nicolas Barthelemy. View Insider Buying and Selling for Fluidigm.

Which institutional investors are buying Fluidigm stock?

FLDM stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Assenagon Asset Management S.A., Dupont Capital Management Corp, Bailard Inc., California Public Employees Retirement System, Tower Research Capital LLC TRC and Cadence Capital Management LLC. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella and Stephen Christopher Linthwaite. View Insider Buying and Selling for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $2.33.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $162.10 million and generates $112.96 million in revenue each year. The medical research company earns $-59,010,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Fluidigm employs 535 workers across the globe.View Additional Information About Fluidigm.

What is Fluidigm's official website?

The official website for Fluidigm is http://www.fluidigm.com/.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]


MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  478 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  778
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel